Novo Nordisk A/S
Latest Novo Nordisk A/S News and Updates

Is Novo Nordisk Trading at a Discount or Premium?
For the last five years, Novo Nordisk (NVO) has been trading at higher multiples when compared with peers.

Why the Majority of Analysts Deem Novartis a ‘Buy’
Novartis met Wall Street analysts’ estimates for EPS (earnings per share) in 4Q16, reporting EPS of $1.12 as estimated but missing revenue estimates.

Novo Nordisk Is Focusing on These Strategic Areas in 2016
With 642 million people expected to suffer from diabetes globally by 2040, the disease is expected to offer multiple growth opportunities for Novo Nordisk.

Analysts’ Recommendations for Sanofi Stock before Q2 Results
Sanofi (SNY) is scheduled to announce its earnings results for the second quarter of fiscal 2018 on July 31.

Norwegian Krone Extended Appreciation Trend Last Week
The Norwegian krone appreciated against the US dollar on October 9, 2015, as a result of positive inflation data.

Novo Nordisk Continues to Be a Leader in the Global Insulin Market
Accounting for a ~46% market share, Novo Nordisk (NVO) is expected to continue to benefit from the positive trends in the global insulin market

Danish Krone Fell and Inflation Was below the Forecasts
The Danish krone fell against the US dollar on November 10, 2015. The inflation figures for October were below the expectations.

Sanofi Stock: How Much Upside Potential Does Wall Street See?
In the second quarter of fiscal 2018, Sanofi (SNY) reported sales of 8.2 billion euros, a YoY (year-over-year) decline in sales as well as profits.

Multinational and Japanese Pharmaceuticals Should Build Alliances
The Japanese pharmaceuticals market is not very welcoming to foreign companies. Similarly, the Japanese population is quite loyal to domestic manufacturers.

What Are the Current Treatment Options for Hemophilia?
Hemophilia treatment primarily includes factor replacement therapy and prolonged half-life therapy such as factor VIII or factor IX infusion.

Analysis of International Mutual Funds: Investor Takeaways
For investors interested in international mutual funds, the next step is to evaluate the investment style, as well as risk and return metrics like the Sharpe ratio and standard deviation.

Swedish Krona and Danish Krone Depreciate after Inflation Reports
The Swedish krona depreciated against the US dollar by more than 1% on December 10, 2015, as inflation levels released below estimates for November.

Performance of Novo Nordisk Stock in 2Q17
Novo Nordisk (NVO) stock has risen ~18.6% in 2Q17. It has risen ~16.9% year-to-date as of July 7, 2017.

Analysts’ Recommendations for GlaxoSmithKline in May
GSK reported EPS of 24.60 British pence on revenue of 7.22 billion pounds, surpassing Wall Street analysts’ consensus estimates.

These Pharma Stocks Offer the Most Upside Potential
In 2018, stock markets, especially in the pharmaceutical sector, have seen heightened volatility.

What Analysts Expect from Pfizer in the Years to Come
Due to Pfizer’s (PFE) strong Innovative Products business and product pipeline, analysts estimate that it will generate $0.54 in earnings per share in 1Q16.

Renaissance Technologies: Analyzing Its Q3 13F
At the end of the third quarter, Bristol-Myers Squibb, Celgene, Biogen, UnitedHealth, and Walmart (WMT) were Renaissance Technologies’ top five buys.

How NVO’s Revenues Are Trending in Fiscal 2019
Novo Nordisk (NVO) has guided for YoY revenue growth of 2% to 5% at a constant exchange rate in fiscal 2019.

What Analysts Recommend for GlaxoSmithKline and Novo Nordisk
GlaxoSmithKline (GSK) is up by 5.02%, and Novo Nordisk (NVO) is up by 10.51% in 2019 on a YTD basis.

GW Pharmaceuticals: Recommendations and Market Capitalization
Wall Street analysts estimate that GWPH stock could increase ~6.7% over the next 12 months.

Sanofi Stock Up 2.8% in September: What Lies Ahead?
On September 27, Sanofi’s (SNY) closing price was $44.84, and its market capitalization was $110.7 billion.

Novartis to Divest Portions of Sandoz US to Aurobindo
Novartis (NVS) announced today that it has agreed to sell select portions of its Sandoz US portfolio to Aurobindo Pharma USA.

Novartis’s Sandoz in Q2 2018
Novartis’s (NVS) Sandoz reported nearly flat revenues at ~$2.46 billion in Q2 2018 compared to $2.45 billion in the second quarter of 2017.

What Drove GlaxoSmithKline’s Consumer Healthcare Segment in Q2
GlaxoSmithKline’s (GSK) Consumer Healthcare segment includes its wellness, oral health, nutrition, and skin health products.

Novo Nordisk’s Long-Acting Insulins: A Performance Overview
Tresiba, Novo Nordisk’s (NVO) long-acting insulin, generated revenues of 3.7 billion Danish kroner in the first half of 2018.

Novo Nordisk: A Financial Overview after the First Half of 2018
Novo Nordisk (NVO) had net revenues of 54.3 billion Danish kroner in H1 2018 compared to 57.1 billion Danish kroner in H1 2017.

Novartis Reports Growth in Q2 2018 Earnings
Novartis (NVS) released its Q2 2018 earnings on July 18 and surpassed Wall Street analysts’ estimates for revenues and EPS.

A Look at Novo Nordisk’s Financial Position
Novo Nordisk (NVO) reported Q1 2018 revenues of 26.9 billion Danish kroner, compared to 28.5 billion Danish kroner in Q1 2017—down ~5% YoY.

How the Healthcare Sector’s Dividend Yield Stacks Up
The healthcare industry has an average dividend yield of 1.9%.

Tresiba Could Significantly Drive Novo Nordisk’s Revenue in 2018
In 4Q17, Novo Nordisk’s (NVO) Tresiba generated revenues of 1.9 billion Danish kroner, which is a ~48% YoY growth in local currencies.

Novartis’s Innovative Medicines Business in 4Q17
Overall, the innovative medicines business accounted for ~67.8% of Novartis’s total revenues.

How AstraZeneca’s Other Products Portfolio Performed in 4Q17
AstraZeneca’s (AZN) other products portfolio reported revenues of ~$1.1 billion during 4Q17, a 17% decline in operating revenues.

How AstraZeneca’s Revenues Trended in 4Q17
AstraZeneca (AZN) reported 2% growth in operating revenues to ~$5.8 billion during 4Q17 as compared to the revenues of ~$5.6 billion during 4Q16.

Semaglutide May Prove to Be an Effective Anti-Obesity Therapy
Novo Nordisk plans to initiate its Phase 3a program, STEP, to study the efficacy of 2.4 mg of semaglutide once per week in obesity indications in 1H18.

Label Expansion May Boost Xultophy’s Sales in 2018
In November 2017, Novo Nordisk (NVO) submitted an application to European regulatory authorities to update Xultophy’s label.

Saxenda May Continue to Lead in the Diabetes Segment in 2018
In 2017, Novo Nordisk’s (NVO) Saxenda sales reached 2.6 billion Danish kroner, a YoY (year-over-year) rise of 64%.

Xultophy May Prove a Strong Growth Driver for NVO in 2018
Novo Nordisk’s (NVO) Xultophy reported sales close to 729 million Danish kroner in 2017.

Novo Nordisk Has Developed a Portfolio of New-Generation Insulins
Novo Nordisk has been creating awareness about the risks of hypoglycemia and the benefits of Tresiba among general practitioners and primary care physicians.

Novo Nordisk Focuses on Creating Buzz about Tresiba’s Benefits
Novo Nordisk (NVO) is anticipating the FDA’s decision related to the inclusion of hypoglycemia data from its DEVOTE and SWITCH studies by the end of 1Q18.

Tresiba Emerged as a Blockbuster Therapy in 2017
In 2017, Novo Nordisk’s (NVO) basal insulin therapy, Tresiba, reported revenue of nearly 7.3 billion Danish kroner and attained blockbuster status.

Will NVO Continue to Lead the Global Insulin Market in 2018?
Novo Nordisk (NVO) has adopted a market-fit strategy, offering insulin products that are suitable for the different demands of patients in different geographies.

Novo Nordisk Has a Broad Portfolio for Type 2 Diabetes Care
According to IQVIA, the global insulin market value grew at a compound average growth rate (or CAGR) of 16.8% from November 2012 to November 2017.

Victoza Continues to Lead in the GLP-1 Segment in 2018
In 3Q17, Novo Nordisk managed to update Victoza’s label in the United States and Europe.

GLP-1 Drug Class May Continue to Drive Growth for Novo Nordisk
According to IQVIA, glucagon-like peptide products currently account for only a 12% share of the global diabetes care market by value.

Sanofi’s Established Prescription Products in 4Q17
Renagel and Renvela reported revenues of 155.0 million euros in 4Q17, a 28.5% decline in operating revenues compared to 4Q16.

Performance of Sanofi’s Business Segments in 4Q17
Sanofi Pasteur reported revenues of ~1.4 billion euros in 4Q17 for 8.7% growth in operating revenues compared to its 4Q16 revenues.

A Look at Ablynx and Sanofi’s Existing Partnership
On January 29, 2018, Sanofi (SNY) announced that it had agreed to acquire Ablynx (ABLX) for 3.9 billion euros.

Highlights of Sanofi’s 3.9 Billion Euro Ablynx Acquisition
On January 29, 2018, Sanofi announced its acquisition of Belgium-based Ablynx for 45 euros per share, amounting to a total of 3.9 billion euros (or $4.8 billion) in cash.

Analysts’ Updates after Sanofi’s Bioverativ Announcement
In this article, we’ll have a look at Wall Street’s recommendations and target prices following Sanofi’s Bioverativ acquisition announcement.

Sanofi Leads the Hemophilia Space on Bioverativ Acquisition
According to Sanofi’s (SNY) 2020 roadmap, the company is focused on sustaining a position of leadership in some of its key markets, including the rare diseases space.

Analysts’ Recommendations for Novartis after Its 4Q17 Earnings
Novartis (NVS) is expected to report earnings per share of $1.26 in 1Q18 compared to EPS of $1.13 in 1Q17.

Novartis’s 4Q17 Earnings: Sandoz Business
Sandoz reported a decline of 4.0% in operating revenues, offset by a 4.0% positive impact of foreign exchange.

How Sanofi Can Benefit from Ablynx Acquisition
On January 29, 2018, Sanofi entered an agreement with Ablynx where Sanofi will acquire all of the outstanding ordinary shares of Ablynx.

Reading the Estimates for Novartis’s Alcon in 4Q17
For 4Q17, Alcon is expected to report growth in revenues, driven by the increased demand for contact lenses and surgical products.

Behind Novartis’s 4Q17 Estimates: Innovative Medicines
The Innovative Medicines segment is expected to report growth in operating revenues for 4Q17.

Behind Novartis’s 4Q17 Earnings: Why Some Expect Revenue Growth
Analysts expect Novartis’s revenues to rise ~3.9% to $12.8 billion in 4Q17, driven by growth in operating revenues across all three segments.

How Is Bioverativ’s Eloctate Positioned Now?
In 3Q17, Bioverativ’s (BIVV) Eloctate generated revenue of $186.3 million, reflecting a 41% rise on a year-over-year (or YoY) basis.

How Is Roche’s Hemlibra Positioned for 2018?
Roche’s (RHHBY) Hemlibra is used for the prevention and reduction of the frequency of bleeding episodes in individuals with hemophilia A with factor VIII inhibitors.

Ozempic Could Boost Novo Nordisk’s Revenue Growth in 2018
In December 2017, the U.S. FDA (Food and Drug Administration) approved Novo Nordisk’s (NVO) Ozempic as an addition to diet and exercise for the improvement of blood sugar levels in individuals with type two diabetes mellitus.

How Did Novo Nordisk’s NovoMix and Human Insulin Perform in 2017?
In 3Q17, Novo Nordisk’s (NVO) NovoMix reported revenues of 2.4 billion Danish krone (or DKK), which reflected ~1% growth on year-over-year (or YoY) basis.

How Novo Nordisk’s Biopharmaceuticals Segment Performed in 3Q17
In 3Q17, Novo Nordisk’s (NVO) hemophilia segment reported revenues of 2.4 billion Danish krone (or DKK), a ~10% increase on a YoY basis.

How Did Novo Nordisk’s Victoza and Saxendra Perform in 3Q17?
In 3Q17, Novo Nordisk’s (NVO) Victoza reported revenues of 5.3 billion Danish krone (or DKK), which reflected ~9% growth on a year-over-year (or YoY) basis.

How Did Novo Nordisk’s Modern Insulin Segment Perform in 3Q17?
In 3Q17, Novo Nordisk’s (NVO) NovoRapid reported revenues of 5.0 billion Danish krone (or DKK), which reflected ~9% growth on year-over-year (or YoY) basis.

Novo Nordisk’s Xultophy, Ryzodeg, and Fiasp Could Boost Revenue Growth in 2018
Novo Nordisk’s (NVO) Xultophy (insulin degludec and liraglutide combination) is used as an addition to diet and exercise for improvement of blood sugar levels in adults with type-2 diabetes mellitus whose blood sugar level could not be controlled adequately with basal insulin.

How Is Novo Nordisk’s New Generation Insulin Segment Positioned after 3Q17?
In 3Q17, Novo Nordisk’s (NVO) new generation insulin generated revenues of 2.1 billion Danish krone (or DKK), which reflected ~93% growth on a year-over-year (or YoY) basis.

Behind Sanofi’s Generics and Consumer Healthcare Business in 3Q17
Sanofi’s (SNY) general medicines and emerging markets sub-segment reported revenues of 433 million euros in 3Q17, representing a 0.9% YoY fall.

How Eli Lilly’s Trajenta, Trulicity, and Basaglar Are Performing
In 3Q17, Eli Lilly’s (LLY) Trajenta generated revenues of $153.3 million, ~33% growth on a year-over-year (or YoY) basis and ~8% growth on a quarter-over-quarter basis.

How Eli Lilly’s Endocrinology Drugs Are Performing
In 3Q17, Eli Lilly’s (LLY) Humalog generated revenues of $696.2 million, ~9% growth on year-over-year (or YoY) basis and 3% growth on a quarter-over-quarter basis.

How Eli Lilly’s Forteo and Jardiance Are Performing
In 3Q17, Eli Lilly’s (LLY) Forteo generated revenues of $441.7 million, ~13% growth on a year-over-year (or YoY) basis and a 1% decline on a quarter-over-quarter basis.

Analysts’ Recommendations for GlaxoSmithKline in November 2017
Wall Street analysts estimate that GlaxoSmithKline’s (GSK) top line could fall 0.8% to ~7.5 billion pounds in 4Q17.

Behind Sanofi’s 3Q17 Revenue Growth
Sanofi (SNY) reported a growth of 4.7% in revenues at constant exchange rates to 9.05 billion euros, compared with 9.03 billion euros in 3Q16.

Novo Nordisk Stock: Performance in 3Q17
Novo Nordisk stock has risen ~12.3% in 3Q17. It has risen ~41.3% year-to-date as of October 20, 2017.

What GlaxoSmithKline’s 3Q17 Performance Tells Us
GSK stock fell ~4.7% in 3Q17 but has risen ~6.0% YTD (year-to-date) as of October 16.

Why Eli Lilly’s Basaglar, Jardiance, and Trajenta Could Witness Steady Growth in 2018
In 1H17, Eli Lilly’s (LLY) Basaglar generated revenues of around $132.6 million, compared with $27.2 million in 1H16.

Behind Merck’s Performance in 3Q17
MRK stock rose ~0.6% in 3Q17 and has risen ~7.7% YTD (year-to-date) as of October 16.

How Is Novo Nordisk’s Victoza Positioned after 2Q17?
In the first half of 2017, Novo Nordisk’s (NVO) Victoza generated revenues of DKK (Danish kroner) 11.5 billion, which reflected a ~21.0% rise on a YoY (year-over-year) basis.

Xultophy Could Substantially Boost Novo Nordisk’s Revenue Growth
In the first half of 2017, Novo Nordisk’s (NVO) Xultophy generated revenues of DKK (Danish kroner) 284.0 million.

BioMarin’s Strong Pipeline Could Be a Long-Term Growth Driver
After success in the company’s phase 1/2 trial with BMN 270, an investigational gene therapy for hemophilia A, BioMarin Pharmaceuticals (BMRN) is expected to start phase 3 trials.

How Merck’s Gardasil and Other Human Vaccines Performed in 2Q17
Merck’s (MRK) Gardasil franchise includes vaccines for the prevention of certain strains of HPV infections that are sexually transmitted.

This Part of Bioverativ’s Pipeline Could Be a Major Long-Term Growth Driver
In June 2017, the FDA accepted Bioverativ’s investigative new drug application for BIVV001, a drug designed to treat prophylaxis from bleeding associated with hemophilia A.

How Are Bioverativ’s Key Drugs Positioned after 2Q17?
In 2Q17, Bioverativ’s Alprolix generated revenues of ~$89.7 million, which represents ~12% growth YoY (year-over-year) and ~4% growth sequentially.

Chart in Focus: AstraZeneca’s Revenues in 2Q17
AstraZeneca (AZN) reported a decrease of ~10% in its top line at ~$5.1 billion for 2Q17, compared to revenues of $5.6 billion for 2Q16.

GlaxoSmithKline’s Consumer Healthcare Business Improved
GlaxoSmithKline (GSK) added new products and improved the supply chain for consumer healthcare products in the last few years.

How Did GlaxoSmithKline’s Segments Perform in 2Q17?
GlaxoSmithKline’s Pharmaceuticals segment reported revenues of 4.36 billion pounds during 2Q17—12% growth compared to 2Q16.

Johnson & Johnson’s Medical Devices Segment in 2Q17
Medical devices segment Johnson & Johnson’s (JNJ) medical devices segment reported revenue of $6.7 billion in 2Q17, a growth of 4.9% from the revenue of $6.4 billion reported in 2Q16. This figure included 5.9% growth in operating revenue, and was partially offset by a 1% foreign exchange impact. Cardiovascular care franchise The cardiovascular care franchise […]

Sanofi’s General Medicines and Consumer Healthcare in 2Q17
General Medicines Sanofi’s (SNY) generic business contributed ~5.1% of its total revenue in 2Q17. The business reported revenue of 442 million euros in 2Q17, an 8% decrease from 2Q16. Revenue fell due to lower sales in US markets, European markets, and emerging markets. This fall was partially offset by the growth in the rest of […]

Performance of Sanofi’s Established Products in 2Q17
Established products Sanofi’s (SNY) established products contributed over 29.5% of its total revenue in 2Q17. Established product revenue, which fell 2.3% at constant exchange rates in 2Q17, stood at 2.6 billion euros. Lower sales of Plavix, Lovenox, Allegra, Myslee, Lasix, and a few other drugs were substantially offset by strong performance by Renagel, Renvela, Aprovel, Synvisc, […]

Sanofi Genzyme Continues Driving Revenue Growth in 2Q17
Sanofi Genzyme In 2Q17, Sanofi Genzyme (SNY) reported revenue growth of 13.5% to 1.7 billion euros. Considering a constant structure and constant exchange rates, the growth was 14.4%. Sanofi Genzyme, which includes product revenue from the multiple sclerosis, rare disease, oncology, and immunology franchises, reported a sales increase of ~14.6% to 1.7 billion euros. This rise was […]

Sanofi’s Revenue Growth in 2Q17
Sanofi’s revenue in 2Q17 At constant exchange rates, Sanofi (SNY) reported revenue growth of ~5.5% between 2Q16 and 2Q17, with revenue rising to 8.7 billion euros from 8.1 billion euros. Structure of the group The above chart shows Sanofi’s segment-wise revenue over the last few quarters. In 2016, Sanofi reorganized itself into five business units: Sanofi […]

Pfizer’s Important Product Developments in 2Q17
Pfizer’s (PFE) innovative health business and essential health business are focusing on growth. To strengthen the innovative health business, the company is focusing on the development of new drugs…

GlaxoSmithKline’s Valuations after Its 2Q17 Earnings
On July 28, 2017, GlaxoSmithKline (GSK) traded at a forward PE multiple of 13.4x, which is slightly lower than the industry average of 15.2x.

Bioverativ’s Research Pipeline May Boost Future Revenues
Bioverativ (BIVV) plans to improve compliance rates for hemophilia patients further by launching therapies with lower dosage frequency.

Bioverativ’s Eloctate Sees More Demand from Hemophilia A Patients
In 1Q17, Bioverativ’s Eloctate witnessed revenues close to $155.9 million, which is about $48.0 million more YoY (year-over-year).

Analysts’ Recommendations for AstraZeneca in 2Q17
Wall Street analysts expect AstraZeneca’s top line to fall ~9.5% to $5.1 billion in 2Q17, compared to $5.6 billion in 2Q16. Its earnings per share are expected to be $0.42 in 2Q17.

Novartis in 2Q17: Performance of Sandoz
Sandoz contributed ~20.0% of total revenues at $2.45 billion in 2Q17, a 5.0% fall compared to $2.58 billion in 2Q16.

Foreign Exchange Impacts Novartis’s Growth in 2Q17
In its earnings release on July 8, 2017, Novartis (NVS) reported flat revenues at constant currencies for 2Q17.

Johnson & Johnson: Consumer Products in 2Q17
The consumer segment Johnson & Johnson’s (JNJ) consumer segment revenue rose 1.7% to $3.5 billion in 2Q17, compared with $3.4 billion in 2Q16. This rise includes operational growth of 2.3%, which was offset by a 0.6% impact of foreign exchange. Baby care franchise The baby care franchise reported revenue of $494 million in 2Q17, a […]

Novartis’s 2Q17 Estimates: Innovative Medicines Segment
The overall contribution of Novartis’s (NVS) Innovative Medicines segment is ~67.0% of its total revenues.

Analysts Expect Novartis’s Revenues to Fall in 2Q17
Analysts expect Novartis’s (NVS) revenues to fall ~1.6% to $12.3 billion in 2Q17 due to the effects of the acquisition and divestiture of some of its products.

Analysts’ Latest Recommendations for Johnson & Johnson
Johnson & Johnson (JNJ) missed Wall Street analysts’ revenue estimates in 1Q17. It reported revenue of $17.8 billion in the quarter.